Edition:
United States

Fibrocell Science Inc (FCSC.OQ)

FCSC.OQ on NASDAQ Stock Exchange Capital Market

2.27USD
18 Jul 2018
Change (% chg)

-- (--)
Prev Close
$2.27
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
65,335
52-wk High
$19.60
52-wk Low
$2.15

Latest Key Developments (Source: Significant Developments)

Fibrocell Announces FDA Allowance Of Investigational New Drug Application For FCX-013
Tuesday, 6 Mar 2018 08:00am EST 

March 6 (Reuters) - Fibrocell Science Inc ::FIBROCELL ANNOUNCES FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR FCX-013 FOR THE TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA.FIBROCELL ANNOUNCES FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR FCX-013 FOR THE TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA.FIBROCELL SCIENCE - U.S. FDA GRANTED IND APPLICATION FOR FCX-013 TO BEGIN CLINICAL TRIALS FOR TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA.FIBROCELL SCIENCE - EXPECTS TO INITIATE ENROLLMENT FOR OPEN LABEL, SINGLE ARM PHASE 1/2 CLINICAL TRIAL IN Q3 2018 FOR FCX-013.FIBROCELL SCIENCE- INTENDS TO INCLUDE PEDIATRIC PATIENTS IN PHASE 2 POST APPROVAL OF SAFETY AND ACTIVITY DATA FROM ADULT PHASE 1 PATIENTS TO FDA.  Full Article

Fibrocell Science Says Submitted IND Application For FCX-013 To Treat Type Of Skin Disorder
Monday, 5 Feb 2018 08:00am EST 

Feb 5 (Reuters) - Fibrocell Science Inc ::FIBROCELL SCIENCE SAYS SUBMITTED INVESTIGATIONAL NEW DRUG APPLICATION FOR FCX-013 FOR TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA​.  Full Article

Fibrocell Science Says Expects IND Filing Of FCX-013 In Q1 2018
Friday, 29 Dec 2017 08:56am EST 

Dec 29 (Reuters) - Fibrocell Science Inc ::FIBROCELL SCIENCE INC SAYS EXPECTS IND FILING OF FCX-013 IN Q1 2018 AND INITIATE SAFETY CLINICAL TRIAL IN 2018 - SEC FILING.  Full Article

Fibrocell Science Q3 loss per share $‍0.02​
Monday, 13 Nov 2017 08:00am EST 

Nov 13 (Reuters) - Fibrocell Science Inc :Fibrocell reports third quarter 2017 financial results and recent highlights.Company believes that its cash and cash equivalents at September 30, 2017 will be sufficient to fund operations into Q2 of 2018​.Fibrocell expects to submit IND application for FCX-013 to FDA in Q4 of 2017, and initiate a human safety clinical trial in 2018​.Fibrocell Science Inc qtrly loss per share $‍0.02​.  Full Article

Fibrocell Science files for common stock offering of up to $23 mln
Monday, 6 Nov 2017 05:51pm EST 

Nov 6 (Reuters) - Fibrocell Science Inc ::Fibrocell Science Inc files for common stock offering of up to $23 million - SEC filing‍​.  Full Article

Fibrocell reports qtrly loss per share $0.97
Wednesday, 9 Aug 2017 08:00am EDT 

Aug 9 (Reuters) - Fibrocell Science Inc :Fibrocell reports second quarter 2017 financial results and recent highlights.Fibrocell Science Inc - ‍Company believes that its cash and cash equivalents at June 30, 2017 will be sufficient to fund operations into Q2 of 2018​.Fibrocell Science Inc qtrly loss per share $0.97.  Full Article

Fibrocell completes dosing of first cohort in phase 1/2 clinical trial of FCX-007 gene therapy
Thursday, 8 Jun 2017 08:00am EDT 

June 8 (Reuters) - Fibrocell Science Inc :Fibrocell completes dosing of first cohort in phase 1/2 clinical trial of FCX-007 gene therapy for treatment of recessive dystrophic epidermolysis bullosa.No product-related adverse events were reported.12-week post-treatment data for safety, mechanism of action and efficacy for multiple patients in phase 1 portion of trial expected in Q3 of 2017.  Full Article

Fibrocell Science Q1 loss per share $0.60
Wednesday, 10 May 2017 08:00am EDT 

May 10 (Reuters) - Fibrocell Science Inc :Fibrocell reports first quarter 2017 financial results and recent operational highlights.Q1 loss per share $0.60.Fibrocell Science Inc - as of march 31, 2017, company had cash and cash equivalents of $20.6 million and working capital of $18.2 million.Fibrocell Science Inc - company believes that its cash and cash equivalents at march 31, 2017 will be sufficient to fund operations into Q2 of 2018.Fibrocell Science Inc - expect to submit investigational new drug application to FDA in q4 2017 for fcx-013.  Full Article

Fibrocell Science reports 2016 financial results
Thursday, 9 Mar 2017 08:00am EST 

Fibrocell Science Inc : Fibrocell reports 2016 financial results and recent operational highlights .Believes cash, cash equivalents at dec 31, 2016 will be sufficient to fund operations into Q2 of 2018.  Full Article

Fibrocell announces convertible preferred stock financing for $8 mln
Tuesday, 7 Mar 2017 04:54pm EST 

Fibrocell Science Inc : Fibrocell announces convertible preferred stock financing for $8.0 million . Fibrocell Science Inc - fibrocell has agreed to sell an aggregate of 8,000 units for a purchase price of $1,000 per unit .Fibrocell Science - intends to use net proceeds of about $7.7 million from offering for continued clinical, pre-clinical development of product candidates.  Full Article

BRIEF-Fibrocell Reports On Interim Results And Progress Of Phase 1/2 Clinical Trial Of FCX-007 Gene Therapy For Recessive Dystrophic Epidermolysis Bullosa

* FIBROCELL REPORTS ON INTERIM RESULTS AND PROGRESS OF PHASE 1/2 CLINICAL TRIAL OF FCX-007 GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA